RU2009107487A - Лечение эндокринной дисфункции с использованием комплексонов железа - Google Patents

Лечение эндокринной дисфункции с использованием комплексонов железа Download PDF

Info

Publication number
RU2009107487A
RU2009107487A RU2009107487/15A RU2009107487A RU2009107487A RU 2009107487 A RU2009107487 A RU 2009107487A RU 2009107487/15 A RU2009107487/15 A RU 2009107487/15A RU 2009107487 A RU2009107487 A RU 2009107487A RU 2009107487 A RU2009107487 A RU 2009107487A
Authority
RU
Russia
Prior art keywords
deferoxamine
iron
complexon
hydroxypyridin
diabetes
Prior art date
Application number
RU2009107487/15A
Other languages
English (en)
Russian (ru)
Inventor
Иоав КАБАНЧИК (IL)
Иоав Кабанчик
Ханспетер НИКК (CH)
Ханспетер Никк
Original Assignee
Новартис АГ (CH)
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис АГ (CH), Новартис Аг filed Critical Новартис АГ (CH)
Publication of RU2009107487A publication Critical patent/RU2009107487A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2009107487/15A 2006-08-04 2007-08-03 Лечение эндокринной дисфункции с использованием комплексонов железа RU2009107487A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06118491.7 2006-08-04
EP06118491 2006-08-04

Publications (1)

Publication Number Publication Date
RU2009107487A true RU2009107487A (ru) 2010-09-10

Family

ID=37594962

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009107487/15A RU2009107487A (ru) 2006-08-04 2007-08-03 Лечение эндокринной дисфункции с использованием комплексонов железа

Country Status (11)

Country Link
US (1) US20100004303A1 (fr)
EP (2) EP2049108A1 (fr)
JP (1) JP2009545547A (fr)
KR (1) KR20090035737A (fr)
CN (1) CN101500561A (fr)
AU (1) AU2007280639A1 (fr)
BR (1) BRPI0715123A2 (fr)
CA (1) CA2659161A1 (fr)
MX (1) MX2009001290A (fr)
RU (1) RU2009107487A (fr)
WO (1) WO2008015021A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
RU2009146126A (ru) * 2007-05-14 2011-06-20 Новартис АГ (CH) Применение хелаторов железа для лечения инфаркта миокарда
WO2009055863A1 (fr) * 2007-11-01 2009-05-07 The University Of Sydney Conjugués de la desferrioxamine, dérivés et analogues
WO2009111611A2 (fr) 2008-03-05 2009-09-11 Proteotech Inc. Composés, compositions et méthodes pour le traitement de l’accumulation du polypeptide amyloïde des îlots (iapp) dans le diabète
WO2010143006A1 (fr) * 2009-06-10 2010-12-16 Carlo Ghisalberti Chélateurs du fer biodisponibles par voie orale dans le traitement d'une maladie intestinale inflammatoire
BR112014012054A2 (pt) * 2011-11-18 2017-05-30 Apotex Tech Inc métodos de tratamento com deferiprona
CN102603964B (zh) * 2012-01-15 2014-03-05 浙江工商大学 水溶性聚合物铁螯合剂及其制备方法和用途
US20210161840A1 (en) * 2018-04-15 2021-06-03 Mordechai Chevion Compositions and methods for treatment of iron overload
KR102674622B1 (ko) * 2021-10-15 2024-06-11 아주대학교산학협력단 데페록사민을 포함하는 근감소증의 예방, 개선 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
EP1565185A4 (fr) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation Chelateurs du fer et compositions pharmaceutiques les renfermant
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
CA2587558A1 (fr) * 2004-11-19 2006-05-26 Shiva Biomedical, Llc Procedes de traitement de la resistance a l'erythropoietine
US20070014764A1 (en) * 2005-07-18 2007-01-18 Andrew Levy Reduction in myocardial infarction size

Also Published As

Publication number Publication date
US20100004303A1 (en) 2010-01-07
AU2007280639A1 (en) 2008-02-07
EP2191829A3 (fr) 2010-08-25
MX2009001290A (es) 2009-02-11
EP2191829A2 (fr) 2010-06-02
KR20090035737A (ko) 2009-04-10
BRPI0715123A2 (pt) 2013-06-04
CA2659161A1 (fr) 2008-02-07
CN101500561A (zh) 2009-08-05
JP2009545547A (ja) 2009-12-24
WO2008015021A1 (fr) 2008-02-07
EP2049108A1 (fr) 2009-04-22

Similar Documents

Publication Publication Date Title
RU2009107487A (ru) Лечение эндокринной дисфункции с использованием комплексонов железа
Sances et al. Naproxen sodium in menstrual migraine prophylaxis: A double‐blind placebo controlled study
Ruottinen et al. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.
CA1184501A (fr) Agent antiparkinsonien
US20090076021A1 (en) Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease
KR20110070929A (ko) 파킨슨병의 치료방법
US20080261958A1 (en) Combination of Organic Compounds
AU2006212772A1 (en) Combination of organic compounds
ZA200307156B (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV.
CA2777746A1 (fr) Composes de benzoimidazole et utilisations de ceux-ci
JP2009545547A5 (fr)
RU2709198C2 (ru) Применение изоксазолиновых соединений для лечения демодекоза
JP2009514896A (ja) メトホルミンおよびメグリチニドの組み合わせ
JP2007512273A (ja) ベータ−３−アドレノセプター作用薬及びプロスタグランジン代謝に影響を及ぼす活性物質から成る医薬組成物
IL277553B1 (en) Preparations for the treatment of neurodegenerative diseases by continuous administration
US20060079579A1 (en) Combinations of valsartan with cox-2 inhibitors
BRPI0720376A2 (pt) Composição farmacêutica que usa aliskiren e avosentan.
JP2003523995A5 (fr)
US20210369664A1 (en) Prophylactic or therapeutic agent for pulmonary hypertension which comprises ppar? agonist
RU2811476C2 (ru) Бета-лактамные соединения или их соли для применения в долгосрочном предотвращении или лечении нарушения метаболизма глюкозы
WO2017126524A1 (fr) Utilisation d'une association d'agents thérapeutiques anti-diabète
JP7327788B2 (ja) 糖化産物生成抑制剤及び医薬組成物
TWI322687B (en) Combination of antidiabetic drugs
NZ545724A (en) Use of a copper chelator for preventing and/or treating cardiovascular disease and/or associated heart failure
US20220142985A1 (en) Agents for treatment of alcohol use disorder

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20111003